Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$122 Mln
P/E Ratio
--
P/B Ratio
0.79
Industry P/E
--
Debt to Equity
--
ROE
-0.84 %
ROCE
-84.34 %
Div. Yield
0 %
Book Value
2.02
EPS
-1.72
CFO
$-551.19 Mln
EBITDA
$-661.85 Mln
Net Profit
$-763.85 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
| -54.03 | -26.92 | -54.58 | -6.56 | -59.38 | -1.35 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Aclaris Therapeutics (ACRS)
| 134.54 | -93.33 | 8.32 | 124.73 | 242.33 | -74.42 | -69.83 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research.... The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 701 Lee Road, Wayne, PA, United States, 19087 Read more
Co-Founder, President, Chairman & Interim CEO
Dr. Neal S. Walker D.O., M.D.
Co-Founder, President, Chairman & Interim CEO
Dr. Neal S. Walker D.O., M.D.
Headquarters
Wayne, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Aclaris Therapeutics Inc (ACRS) stood at $ 220 Mln as on 31-Dec-24
The share price of Aclaris Therapeutics Inc (ACRS) is $1.14 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Aclaris Therapeutics Inc (ACRS) has given a return of -59.38% in the last 3 years.
Aclaris Therapeutics Inc (ACRS) has a market capitalisation of $ 122 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Aclaris Therapeutics Inc (ACRS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aclaris Therapeutics Inc (ACRS) and enter the required number of quantities and click on buy to purchase the shares of Aclaris Therapeutics Inc (ACRS).
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 701 Lee Road, Wayne, PA, United States, 19087
The CEO & director of Dr. Neal S. Walker D.O., M.D.. is Aclaris Therapeutics Inc (ACRS), and CFO & Sr. VP is Dr. Neal S. Walker D.O., M.D..
There is no promoter pledging in Aclaris Therapeutics Inc (ACRS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Aclaris Therapeutics Inc. (ACRS) | Ratios |
|---|---|
|
Return on equity(%)
|
-84.46
|
|
Operating margin(%)
|
-280.59
|
|
Net Margin(%)
|
-705.48
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Aclaris Therapeutics Inc (ACRS) was $0 Mln.
$0.01
(
